With increasing hematopoietic stem cell transplant (HSCT) activity and improvement in
outcomes, there are many thousands of HSCT survivors currently being followed by non …

The prevalence of autologous and allogeneic hematopoietic cell transplantation (HCT)
survivors continues to increase. Among patients whose disease remains in remission for the …

Advances in transplantation techniques and supportive care strategies have resulted in a
significant improvement in survival of those who have undergone treatment. However …

Hematopoietic stem cell transplantation (HSCT) offers the opportunity for cure to patients
with leukemia, lymphoma and severe non-malignant diseases. More than 40,000 HSCTs …

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative
treatment for over 70 benign and malignant hematologic and immunological processes …

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for
various malignant and non-malignant diseases. Many patients have now been followed for …

Hematopoietic cell transplantation (HCT) is an established curative option for a variety of
hematologic malignancies. Liberalization in the indications for transplantation coupled with …

Survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk of developing
long-term complications such as subsequent malignancies and cardiopulmonary …

Continual advances in hematopoietic cell transplantation (HCT) have greatly improved early
transplantation-related mortality and broadened the applicability of this intense but curative …

HEMATOPOIETIC STEM CELL TRANSPLANTATION has been used for many years to treat
various malignant and nonmalignant hematologic conditions. However, the high-dose …